
Switching to Tirzepatide Shows Greater Benefit Than Escalating Dulaglutide in T2D, Obesity
Patients with inadequately controlled type 2 diabetes and obesity experienced greater HbA1c reduction and weight loss after switching treatment to tirzepatide rather than escalating current dulaglutide doses.1 These findings, from the phase 4 SURPASS- …